Article

Received 17.04.2023

Revised 11.07.2023

Accepted 31.08.2023

Retrieved from Vol. 13, No. 2, 2023

Pages 290 -303

Pomohaibo, V., Berezan, O., & Petrushov, A. (2023). Genetics of cannabis addiction. Psychology and Personality, 13(2), 290-303. https://doi.org/10.33989/2226-4078.2023.2.288315

Genetics of cannabis addiction

Valentyn Pomohaibo Oleksii Berezan Andrii Petrushov

Addiction to cannabis is characterized by a strong inner urge to use this substance. It is diagnosed when there is daily use of it for at least one month. Cannabis is the third most commonly used drug in the world after alcohol and tobacco. It is used by almost 4% of the world՚ s population aged 15-64 years. This showing varies between 2.8% and 5.1% depending on the country and ethnicity. Level of cannabis use and dependence are about twice as high among men as among women. The heritability of cannabis addiction is about 55%. There were identified 14 genes that are most significantly involved in this mental disorder: ANKFN1, CHRNA2, CADM2, SDK1, ZNF704, NCAM1, RABEP2, SMG6, INTS7, PI4K2B, CSMD1, CST7, ACSS1 and SCN9A. They are located in different chromosomes and are characterized by the presence of single-nucleotide polymorphisms of different localization. Other variants of these genes can be involved in a different number (from 10 to 350) of various, mainly mental disorders and oncological diseases. Candidate genes for cannabis use problems have been identified also ‒ CNR1, GABRA2, FAAH and ABCB1, but attempts to confirm them are still controversial. Nevertheless, it is worth paying attention to two of them ‒ CNR1 and ABCB1, which are directly involved in the metabolism of cannabinoids in the human body. In further studies of genetics of cannabis addiction, it is necessary to identify and analyze all biological and individual factors that influence the development of this mental disorder. For this, first of all, it is necessary to identify all the genes involved in the metabolism of cannabis in the human body. In addition, in these studies, it is necessary to use not only genetic, but also epigenetic approaches, the results of which will contribute to the development of new methods of treatment of the disorder

cannabis addiction, mental disorders, genetics, identified genes, single nucleotide polymorphisms, candidate genes, epigenetics

[1] Agrawal, A., et al. (2011). A genome-wide association study of DSM-IV cannabis dependence. Addiction Biology, 16(3), 514-518. doi: 10.1111/j.1369-1600.2010.00255.x.

[2] Boschen, K.E., Keller, S.M., Roth, T. L., & Klintsova, A.Y. (2018). Epigenetic mechanisms in alcohol- and adversity-induced developmental origins of neurobehavioral functioning. Neurotoxicology and Teratology, 66, 63-79. doi: 10.1016/j.ntt.2017.12.009. 

[3] Demontis, D., et al. (2019). Genome-wide association study implicates CHRNA2 in cannabis use disorder. Nature Neuroscience, 22(7), 1066-1074. doi: 10.1038/s41593-019-0416-1. 

[4] GeneCards®: The Human Gene Database. (n.d). Retrieved from http://www.genecards.org/.

[5] Hillmer, A., Chawar, C., Sanger, S., D'Elia, A., Butt, M., Kapoor, R., Kapczinski, F., Thabane, L., & Samaan, Z. (2021). Genetic basis of cannabis use: a systematic review. BMC Medical Genomics, 14(1), article number 203. doi: 10.1186/s12920-021-01035-5. 

[6] ICD-11 for Mortality and Morbidity Statistics. (n.d). Retrieved from https://icd.who.int/browse/2024-01/mms/en.

[7] MalaCards: The Human Disease Database. (n.d). Retrieved from http://www.malacards.org/.

[8] NCBI. National Center for Biotechnology Information. (n.d). Retrieved from https://www.ncbi.nlm.nih.gov/gene/.

[9] Pasman, J.A.,  et al. (2018). GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. Nature Neuroscience, 21(9), 1161-1170. doi: 10.1038/s41593-018-0206-1. 

[10] Pomohaibo, V., & Berezan, O. (2020b). Genetics of generalized anxiety disorder. Psychology and Personality, 10(2), 280-291. doi: 10.33989/2226-4078.2020.2.211928. 

[11] Pomohaibo, V., Berezan, O., & Petrushov, A. (2017). Genetics of autism spectrum disorders. World of Medicine and Biology, 1(59), 208-212.

[12] Pomohaibo, V., Berezan, O., & Petrushov, A. (2018a). Genetics of attention-deficit/hyperactivity disorder. Psychology and Personality, 8(1), 171-182.

[13] Pomohaibo, V., Berezan, O., & Petrushov, A. (2018b). Genetics of specific learning disorder. Psychology and Personality, 8(2), 197-207. 

[14] Pomohaibo, V., Berezan, O., & Petrushov, A. (2018c). Genetics of bipolar disorder. Bulletin of Problems in Biology and Medicine, 2(147), 62-65.

[15] Pomohaibo, V., Berezan, O., & Petrushov, A. (2019a). Schizophrenia: The search for genetic risk factors. Psychology and Personality, 9(1), 241-252. doi:  10.5281/zenodo.2560068. 

[16] Pomohaibo, V., Berezan, O., & Petrushov, A. (2019b). Genetics of major depressive disorder. Bulletin of Problems in Biology and Medicine, 2(149), 40-45. doi: 10.29254/2077-4214-2019-1-2-149-40-45. 

[17] Pomohaibo, V., Berezan, O., & Petrushov, A. (2020a). Genetics of intellectual disability. Psychology and Personality, 10(1), 195-251. doi: 10.33989/2226-4078.2020.1.195251. 

[18] Pomohaibo, V., Berezan, O., & Petrushov, A. (2021b). Genetics of phobic disorders. Psychology and Personality, 11(2), 245-256. doi:  10.33989/2226-4078.2021.2.239990. 

[19] Pomohaibo, V., Berezan, O., & Petrushov, A. (2022a). Genetics of paranoidpersonalitydisorder. Psychology and Personality, 12(1), 198-211. doi: 10.33989/2226-4078.2022.1.252067. 

[20] Pomohaibo, V., Berezan, O., & Petrushov, A. (2022b). The genetics of epilepsy. Psychology and Personality, 12(2), 255-266. doi: 10.33989/2226-4078.2022.2.265503. 

[21] Pomohaibo, V., Berezan, O., & Petrushov, A. (2023). Genetics of stuttering. Psychology and Personality, 13(1), 165-177. doi: 10.33989/2226-4078.2023.1.274744. 

[22] Pomohaibo, V., Berezan, O., & Petrushov, O. (2021a). Genetics of obsessive-compulsive disorder. Psychology and Personality, 11(1), 270-280. doi: 10.33989/2226-4078.2021.1.227328. 

[23] Preedy V.R. (2017). Handbook of cannabis and related pathologies: Biology, pharmacology, diagnosis, and treatment.London: Academic Press.

[24] Sherva, R., Wang, Q., Kranzler, H., Zhao, H., Koesterer, R., Herman, A., Farrer, L.A., & Gelernter, J. (2016). Genome-wide association study of cannabis dependence severity, novel risk variants, and shared genetic risks. JAMA Psychiatry, 73(5), 472-480. doi: 10.1001/jamapsychiatry.2016.0036. 

[25] Stoffel, M., Aguilar-Raab, C., Rahn, S., Steinhilber, B., Witt, S.H., Alexander, N., & Ditzen, B. (2019). Effects of mindfulness-based stress prevention on serotonin transporter gene methylation. Psychotherapy and Psychosomatics, 88(5), 317-319. doi: 10.1159/000501646. 

[26] Verweij, K.J., Zietsch, B.P., Lynskey, M.T., Medland, S.E., Neale, M.C., Martin, N.G., Boomsma, D.I., & Vink, J.M. (2010). Genetic and environmental influences on cannabis use initiation and problematic use: A meta-analysis of twin studies. Addiction (Abingdon, England), 105(3), 417-430. doi: 10.1111/j.1360-0443.2009.02831.x. 

[27] World Drug Report 2021. (2021). Retrieved from https://www.unodc.org/unodc/en/data-and-analysis/wdr2021.html.

https://doi.org/10.33989/2226-4078.2023.2.288315